Antidepressant use in children and adolescents diagnosed with major depressive disorder: What can we learn from published data?

Reviews on Recent Clinical Trials

Volumn 5, Issue 1, 2010, Pages 63-75

  Gentile, Salvatore ^a  

^a ASL Salerno   (Italy)

Author keywords

Adolescents; Antidepressants; Children; Effectiveness; Major depressive disorder

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENCE; ARTICLE; BORDERLINE STATE; CHILDHOOD DISEASE; CHRONIC PAIN; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR DEPRESSION; MANIA; MEDICAL LITERATURE; MEDICAL RESEARCH; MOOD DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PUBLICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AGE; CHILD; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADOLESCENT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 77954750370     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488710790820517     Document Type: Article

References (112)

1. Son SE, Kirchner JT. Depression in children and adolescents. Am Family Phys, 2000. Available from: http://www.aafp.org/afp/20001115/2297.html.[Accessed: 7 February, 2009].
2. Luby JL, Belden AC, Tandem M, Spitznagel E. Preschool depression: homotypic continuity and course over 24 months. Arch Gen Psychiatry 2009; 66(8): 897-905.
3. Jellinek MS, Snyder JB. Depression and suicide in children and adolescents. Pediatr Rev 1998; 19: 255-64.
4. Wolraich M, Felice ME, Drotar D. The classification of child and adolescent mental diagnoses in primary care: diagnostic and statistical manual for primary care (DSM-PC) child and adolescent version. Elk Grove Village, Ill.: American Academy of Pediatrics, 1996.
5. Kovacs M, Akiskal HS, Gatsonis C, Parrone PL. Childhood-onset dysthymic disorder: clinical features and prospective naturalistic outcome. Arch Gen Psychiatry 1994; 51: 365-74.
6. Weller EB, Weller RA, Svadjian H. Mood disorders. In: Lewis M, Ed. Child and adolescent psychiatry: a comprehensive textbook. Baltimore: Williams & Wilkins, 1996; pp. 650-5.
7. Wiggins A, Browne MO, Bearsley-Smith C, Villanueva E. Depressive disorders among adolescents managed in a child and adoles-cent mental health service. Austr Psychiatry 2010 [Epub ahead of print].
8. Office of the Surgeon General. The Surgeon General's call to action to prevent suicide. Washington, DC, Department of Health and Human Services 1999.
9. National Center for Injury and Prevention Control. Suicide: Fact sheet. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5635a2.htm.[Accessed: 7 February, 2009].
10. 2005-2009 Statewide Comprehensive Plan for Mental Health Service Services. Chapter 6: Children and Depression. Available from: http://www.omh.state.ny.us/omhweb/Statewideplan/2005/chapter6. htm. Accessed on: 7 February, 2009].
11. Bennett K, Teeling M, Feely J. Overprescribing antidepressants to children: pharmacoepidemiological study in primary care. BMJ 2005; 331:1451-2.
12. Mitchell B, Carleton B, Smith A, Prosser R, Brownell M, Kozyrskyi A. Trends in psychostimulant and antidepressant use by children in 2 Canadian provinces. Can J Psychiatry 2008; 53(3): 152-9.
13. Fegert JM, Kölch M, Zito JM, Glaeske G, Jahnsen K. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 2006; 16(1-2): 197-206.
14. Hsia Y, Maclennan K. Rise in psychotropic drug prescribing in children and adolescents during 1992-2001: a population-based study in the UK. Eur J Epidemiol 2009 [Epub ahead of print].
15. Clavenna C, Bonati M, Rossi E, De Rosa M. Increase in nonevidence based use of antidepressants in children is cause for concern. BMJ 2004; 328(7441): 711-2.
16. FDA talk paper. Fdaňapproves Prozac for Pediatric Use to Treat Depression and OCD. Available from: http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01187.html. [Accessed: 7 February 2009].
17. U.S. Food and Drug Administration. Public health advisory on suicidality in children and adolescents being treated with antide-pressant medications, October 15, 2004. Available from: http://www.medscape.com/viewarticle/491448[Accessed on: 28 December, 2008].
18. FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html[Accessed: 28 December, 2008].
19. Adverse Drug Reactions Advisory Committee. Use of SSRI antidepressants in children and adolescents. Available from: http://www.tga.gov.au/adr/adrac_ssri.htm [Accessed: 1 November, 2008].
20. Canadian Psychiatric Association Bulletin. Health Canada to examine SSRIs in children, April 2004. Available from: http://ww1.cpa- apc.org:8080/Publications/Archives/Bulletin/2004/ april/news32En.asp[Accessed on: 28 December, 2008].
21. National Institute of Mental Health. Antidepressant medications for children and adolescents: information for parents and caregivers. Available from: http://ww.mimh.nih.gov/health/topics/child-and-adolescent-mental-health/antidepressant.htm[Accessed: 1 November, 2008].
22. Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and the risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004; 18(15): 1119-32.
23. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332-9.
24. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164: 1356-63.
25. Lucas AR, Lockett HJ, Grimm FG. Amitriptyline in childhood depression. Dis Nerv Syst 1965; 26:105-10.
26. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram in the treatment of major depression in children and adolescents. Am J Psychiatry 2004; 161:1079-83.
27. Van Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hultén A. A randomized, placebo-controlled study of citalopram in adolescents with major depressive disorders. J Clin Psychopharmacol 2006; 26: 311-5.
28. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A doubleblind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 280-8.
29. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo- controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48(7): 721-9.
30. Boulos C, Kutcher S, Gardner D, Young E. An open naturalistic trial of fluoxetine in adolescents and young adults with treatment- resistant major depression. J Child Adolesc Psychopharmacol 1992; 2(2): 103-11.
31. Ghaziuddin N, Naylor M, King CA. Fluoxetine in tricyclic refractory depression in adolescents. Depress Anx 1994 1995; 2: 287-91.
32. Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990;14: 791-5.
33. Emslie GJ, Rush J, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031-7.
34. Emslie GJ, Rush J, Weinberg WA, et al. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anx 1998; 7: 32-9.
35. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized trial. J Am Acad Child Adolesc Psychiatry 2002; 41(10): 1205-15.
36. Nilsson M, Joliat MJ, Miner EB, Brown EB, Heiligenstein JH. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychophar- macol 2004;14(3): 412-7.
37. Emslie GJ, Heiligenstein JH, Hoog S, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43(11): 1397-1405.
38. Heiligenstein JH, Hoog SL, Wagner KD, et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psycho-pharmacol 2006; 16(1): 207-17.
39. Emslie GJ, Kennard BD, Mayes TL, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008; 165: 459-67.
40. Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N. Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacol 1992; 2(4): 259-64.
41. Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. Br Med J 2007; 335(7611): 142.
42. Treatment for Adolescent with Depression Study" (TADS) Team. Treatment for Adolescent with Depression Study (TADS) randomized controlled trial. Fluoxetine, cognitive-behavioral therapy and their combination for adolescents with depression. JAMA 2004; 292(7): 807-20.
43. Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the Treatment for Adolescent with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45(12): 1404-11.
44. Kennard B, Silva S, Tonev S, et al. Remission and recovery in the Treatment for Adolescent with Depression Study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry 2009; 48(2):187-96.
45. Rodhe P, Silva SG, Tonev ST, et al. Achievement and maintenance of sustained response during the treatment for adolescent with depression study continuation and maintenance therapy. Arch Gen Psychiatry 2008; 65(4): 447-55.
46. Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescent with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006; 45(12): 1440-55.
47. Treatment for Adolescent with Depression Study" (TADS) Team. The Treatment for Adolescent with Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 2009; 166: 1141-9.
48. Apter A, Ratzoni G, King RA, et al. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 1994; 33(3): 342-8.
49. Diler RS, Lut T, Ayse A. Withdrawal symptoms associated with paroxetine discontinuation in a nine-year-old boy. J Clin Psychopharmacol 2000; 20(5): 586-7.
50. Findling RL, Nucci G, Piergies AA, et al. Multiple dose pharma- cokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsycho-pharmacology 2006; 31:1274-85.
51. Braconnier A, Le Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a randomized, multicenter, double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 2003; 42(1): 22-9.
52. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40(7): 762-72.
53. Emslie GJ, Wagner KD, Kutcher S, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2006; 45(6): 709-19.
54. Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine treatment in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2006; 16(1): 59-75.
55. Alderman J, Wolkow R, Chung M, Johnston HF. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 1998; 37(4): 386-94.
56. Tierney E, Joshi PT, LLinas JF, et al. Sertraline for major depression in children and adolescents: preliminary clinical experience. J Child Adolesc Psychopharmacol 1995; 5: 13-27.
57. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290(8): 1033-41.
58. Rynn M, Wagner KD, Donnelly C, et al. Long-term sertraline treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychcopharmacol 2006; (16): 103-16.
59. Donnelly CL, Wagner KD, Rynn M, et al. Sertraline in children and adolescents with major depressive disorder. J Am Acad Child Adolesc Psychiatry 2006; 45(10): 1162-70.
60. Melvin GA, Tonge BJ, King NJ, Heyne D, Gordon MS, Klimkeit E. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry 2006; 45(10): 1151-61.
61. Desarkar P, Das A, Sinha VK. Duloxetine for childhood depression with pain and dissociative symptoms. Eur Child Adolesc Psychiatry 2006; 15(8): 496-9.
62. Meighen KG. Duloxetine treatment of pediatric chronic pain and comorbid major depressive disorder. J Child Adolesc Psychopharmacol 2007; 17(1): 121-7.
63. Delgado SV, Saldaňa SN, Barzman DH. Response to duloxetine in a depressed, treatment-resistant adolescent female. J Child Adolesc Psychopharmacol 2007; 17(6): 889-4.
64. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive-behavioral therapy for adolescents with SSRI-resistant depression. The TORDIA randomized controlled trial. JAMA 2008; 299(8): 901-13.
65. Asarnow JR, Emslie G, Clarke G, et al. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 2009; 48(3): 331-40.
66. Mandoki MW, Tapia MR, Tapia MA, Summer GS, Parker JL. Venlafaxine in the treatment of children and adolescent with major depression. Psychopharmacol Bull 1997; 33(1): 149-153.
67. Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007; 46(4): 479-88.
68. Kye CH, Waterman GS, Ryan ND, et al. A randomized, controlled trial of amitriptyline in the acute treatment of in adolescent major depression. J Am Acad Child Adolesc Psychiatry 1996; 35(9): 1139-44.
69. Kutcher S, Boulos C, Ward B, et al. Response to desipramine treatment in adolescent depression: a fixed-dose, placebo- controlled trial. J Am Acad Child Adolesc Psychiatry 1994; 33(5): 686-94.
70. Klein RG, Mannuzza S, Koplewicz HS, et al. Adolescent depression: controlled desipramine treatment amd atypical features. Depress Anxiety 1998; 7: 15-31.
71. Pulgh-Antich J, Perel JM, Lupatkin W, et al. Imipramine in prepubertal major depressive symptoms. Arch Gen Psychiatry 1987; 44: 81-9.
72. Ryan ND, Pulgh-Antich J, Cooper T, et al. Imipramine in adolescent major depression: plasma levels and clinical response. Acta Psychiatr Scand 1986; 73: 275-88.
73. Strober M, Freeman R, Rigali J. The pharmacotherapy of depressive illness in adolescence: I: an open label trial of imipramine. Psychopharmacol Bull 1990; 26(1): 80-4.
74. Petti TA, Law III W. Imipramine-treatment of depressed children: a double-blind, pilot study. J Clin Psychopharmacol 1982; 2(2): 107-10.
75. Geller B, Cooper TB, McCombs HG, Graham D, Wells J. Double-blind, placebo-controlled study of nortriptyline in depressed children using a "fixed plasma level" design. Psychopharmacol Bull 1989; 25(1): 101-8.
76. Geller B, Cooper TB, Graham DL, Marsteller FA, Bryant DM. Double-blind, placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design. Psycho-pharmacol Bull 1990; 26(1): 85-90.
77. Geller B, Fox LW, Fletcher M. Effect of tricyclic antidepressants on switching to mania and the onset of bipolarity in depressed 6- to 12-year-olds. J Am Acad Child Adolesc Psychiatry 1993; 32(1): 43-50.
78. Frommer EA. Treatment of childhood depression with antidepressant drugs. Br Med J 1967; 3:729-32.
79. Emslie GJ, Findling RL, Rynn MA, Marcus RN. Efficacy and safety of nefazodone in the treatment of adolescents with major depressive disorder Abstract]. J Child Adolesc Psychopharmacol 2002; 12: 299.
80. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in young depression. J Child Psychol Psychiatry 2005; 46: 735-54.
81. Cohen D, Deniau E, Maturana A, et al. Are child and adolescent response to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials. PLoS One 2008; 3(7): e2632.
82. Beardslee WR, Versage EM, Gladstone TR. Children of affectively ill parents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1988; 37: 1134-41.
83. Weissman MM, Warner V, Wickamaratne P, Moreau P, Olfson M. Offspring of depressed parents: 10 years later. Arch Gen Psychiatry 1997; 54: 932-40.
84. Weissman MM, Wickamaratne P, Nomura P, Pilowsky D, Verdeli H. Offspring of depressed parents: 20 years later. Am J Psychiatry 2006; 163: 1001-8.
85. Weissman MM, Wickamaratne P, Pilowsky D, et al. Remission in maternal depression and child psychopathology: a STAR*D-child report. JAMA 2006; 295: 1389-98.
86. Foster CE, Webster MC, Weissman MM, et al. Remission of maternal depression: relation to family functioning and youth internalizing and externalizing symptoms. J Clin Child Adolesc Psychol 2008; 37(4): 714-24.
87. Kennard BD, Hughes BA, Stewart SM, et al. Maternal depressive symptoms in pediatric major depressive disorder: relationship to acute treatment outcome. J Am Acad Child Adolesc Psychiatry 2008; 47(6): 694-9.
88. Davé S, Sherr L, Senior R, Nazareth I. Major paternal depression and child consultation for developmental and behavioural problems. Br J Gen Pract 2009; 59(560): 180-5.
89. McLaughlin KA, Hatzenbuehler ML. Mechanisms linking stressful life events and mental health problems in a prospective, community-based sample of adolescents. J Adolesc Health 2009; 44(2): 153-60.
90. Primack BA, Swanier B, Georgiopoulos AM, Land SR, Fine MJ. Association between media use in adolescence and depression in young adulthood: a Longitudinal Study. Arch Gen Psychiatry 2009; 66(2): 181-8.
91. Hammen C, Brennan PA, Keenan-Miller D, Nathaniel R. Early onset recurrent subtype of adolescent depression: clinical and psychosocial correlates. J Child Psychol Psychiatry 2008; 49(4): 433-40.
92. Brausch AM, Gutierrez PM. The role of body image and disordered eating as risk factors for depression and suicidal ideation in adolescents. Suicide Life Threat Behav 2009; 39(1): 58-71.
93. Garber J, Clarke GN, Weersing VR, et al. Prevention of depression in at-risk adolescents: a randomized controlled trials. JAMA 2009; 301(21): 2215-24.
94. Fleming JE, Boyle MH, Offord DR. The outcome of adolescent depression in the ontario child health study follow-up. J Am Acad Child Adolesc Psychiatry 1993; 32(1): 28-33.
95. Schoenstadt A. Childhood depression. Available from: http://depression.emedtv.com/childhood-depression/outcome-of-childhood-depression-p2.html[Accessed: 28 February, 2009].
96. Kasen S, Cohen P, Skodol AE, Johnson JG, Smailes E, Brook JS. childhood depression and adult personality disorder. Alternative Pathways of Continuity. Arch Gen Psychiatry 2001; 58: 231-6.
97. US Preventive Services Task Force. Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force recommendation statement. Pediatrics 2009; 123(4): 1223-8.
98. Gentile S. Atypical antipsychotic for the treatment of bipolar disorder: more shadows than lights. CNS Drugs 2007; 21(5): 367-87.
99. Gentile S. Contributing factors to weight gain during long-term treatment with second-generation antipsychotics: a systematic appraisal and clinical implications. Obes Rev 2009; 10(5): 527-42.
100. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults. Arch Gen Psychiatry 2006; 63: 865-72.
101. DG news. Escitalopram represents the second antidepressant to be approved for major depressive disorder in adolescents. Available from: http://www.docguide.com/news/content.nsf/news/8525710 20057CCF68525757F0067B7C3 [Accessed: 28 March 2009].
102. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrowe D, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341-5.
103. Vitiello B, Silva SG, Rohde P, et al. Suicidal events in the treatment for adolescents with depression study (TADS). J Clin Psychiatry 2009; 70(5): 741-7.
104. Reinblatt SP, dosReis S, Walkup JT, Riddle MA. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents. J Child Adolesc Psycho-pharmacol 2009; 19: 119-26.
105. Findling RL, Lingler J, Rowles BM, McNamara NK, Calabrese JR. A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. J Child Adolesc Psychopharmacol 2008; 18(6): 615-21.
106. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006; 63: 865-72.
107. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in SSRI adolescents (TORDIA) study. Am J Psychiatry 2009; 166(4): 418-26.
108. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric anti-depressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683-96.
109. Benjamin DK Jr, Smith B, Sun JM, et al. Safety and transparency of pediatric drug trials. Arch Pediatr Adolesc Med 2009; 163(12); 1080-6.
110. Clarke G, Debar L, Lynch F, et al. A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medications. J Am Acad Child Adolesc Psychiatry 2005; 44(9): 888-98.
111. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006; 63: 865-72.
112. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in SSRI adolescents (TORDIA) study. Am J Psychiatry 2009 [Epub ahead of print].